CompaniesInnocrin Pharmaceuticals

Innocrin Pharmaceuticals

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (10)
View all

Total Trials

10

As Lead Sponsor

5

As Collaborator

5

Total Enrollment

30,287

By Phase

PHASE2/PHASE3: 1PHASE1/PHASE2: 2PHASE2: 3PHASE4: 1PHASE1: 1

By Status

COMPLETED: 8ACTIVE_NOT_RECRUITING: 1RECRUITING: 1
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
Today
NCT00404989
NCT00578240
Hover over trial bars to see details

Recent Trials

NCT05033743Collaborator
Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study
PHASE2/PHASE3Completed
24 participants
Started: Jul 9, 2021 · Completed: Oct 7, 2022
NCT02580448Lead Sponsor
CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)
PHASE1/PHASE2Completed
175 participants
Started: Aug 31, 2015 · Completed: Jan 31, 2019
NCT02445976Lead Sponsor
Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.
PHASE2Completed
197 participants
Started: May 31, 2015 · Completed: Jan 31, 2019
NCT02361086Lead Sponsor
A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer
PHASE1/PHASE2Completed
21 participants
Started: Jun 30, 2014 · Completed: Jun 30, 2018
NCT02130700Lead Sponsor
Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer
PHASE2Completed
17 participants
Started: Apr 30, 2014 · Completed: Nov 30, 2017
View all 10 trials →
Funding History (3)
D
Jul 13, 2017
Filing
D
Apr 21, 2015
Filing
D
Dec 11, 2014
Filing